The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease

Cunha, Marcelo Livorsi da; Wagner, Jairo; Osawa, Akemi; Scheinberg, Morton

doi:10.1093/rheumatology/kep441

Cited by 18 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RA (in more than 90 countries worldwide) [36][37][38][39][40][41][42] Castleman's disease (in Japan) [52,53] Systemic and polyarticular JIA (in Japan) [57][58][59] Candidate diseases for tocilizumab therapy: Systemic autoimmune diseases SLE [130] Systemic sclerosis [115] Giant cell arteritis and Takayasu arteritis [90,91] Polymyositis Organ specific autoimmune diseases Crohn's disease [73] Relapsing polychondritis [108] Multiple sclerosis, neuromyelitis optica Acquired hemophilia A [149] Chronic inflammatory diseases Adult-onset Still's disease [61][62][63][64][65][66][67][68] Reactive AA amyloidosis [48][49][50][51] Polymyalgia rheumatica [80,91] RS3PE [85] Spondyloarthritides [100,[102][103][104][105] Behcet's disease Uveitis GVHD [150] Autoinflammatory diseases (TRAPS) [152] Tocilizumab has been approved as a biological drug for the treatment of RA, Castleman's disease and juvenile idiopathic arthritis, and is expected to be applicable to various other autoimmune and inflammatory diseases. Abbreviations: RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; RS3PE, remitting seronegative, symmetrical synovitis with pitti...…”

Section: Conflict Of Interestmentioning

confidence: 99%

“…Pathologically it resembles systemic JIA and is considered to be an adult-onset type of systemic JIA. Again, several case and pilot studies reported that tocilizumab treatment improved clinical symptoms and signs of AOSD patients who had been refractory to conventional treatments [61][62][63][64][65][66][67][68]. The clinical efficacy suggests that tocilizumab may become a first line biologic for the treatment of systemic JIA and AOSD.…”

Section: Systemic Juvenile Idiopathic Arthritis and Adult-onset Stillmentioning

confidence: 99%

“…Adult-onset Still's disease [61][62][63][64][65][66][67][68] Reactive AA amyloidosis [48][49][50][51] Polymyalgia rheumatica [80,91] RS3PE [85] Spondyloarthritides [100,[102][103][104][105] Behcet's disease Uveitis GVHD [150] Autoinflammatory diseases (TRAPS) [152] Tocilizumab has been approved as a biological drug for the treatment of RA, Castleman's disease and juvenile idiopathic arthritis, and is expected to be applicable to various other autoimmune and inflammatory diseases. Abbreviations: RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; RS3PE, remitting seronegative, symmetrical synovitis with pitting edema; GVHD, graft-versus-host disease; TRAPS, tumor necrosis factor associated periodic syndrome.…”

Section: Chronic Inflammatory Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

2011

View full text Add to dashboard Cite

Interleukin (IL)‐6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL‐6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti‐IL‐6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL‐6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.

show abstract

Section: Conflict Of Interestmentioning

confidence: 99%

Section: Systemic Juvenile Idiopathic Arthritis and Adult-onset Stillmentioning

confidence: 99%

Section: Chronic Inflammatory Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

2011

View full text Add to dashboard Cite

show abstract

“…Cunha et al presented two AOSD patients receiving TOC because of active disease in spite of continuous prednisolone treatment with a daily dose of 20 mg [13]. Both patients underwent an 18 F-Flourodeoxyglucose positron emission tomography computer tomography ( 18 FDG-PET CT) scan before TOC therapy showing pathological 18 FDG uptake in spleen and bone marrow (patient 1) as well as quadriceps muscle and iliac bone (patient 2).…”

Section: Review Of the Literature And Discussionmentioning

confidence: 99%

Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature

Thonhofer

Hiller²,

Just

et al. 2011

Rheumatol Int

View full text Add to dashboard Cite

Adult-onset Still's disease (AOSD) is empirically treated with nonsteroidal anti-inflammatory drugs, corticosteroids, conventional disease-modifying antirheumatic drugs, tumor necrosis factor-blocking agents or anakinra. The monoclonal anti-interleukin (IL)-6 antibody tocilicumab (TOC) has recently been approved for the treatment of rheumatoid arthritis and may be an attractive therapeutic option for AOSD as well. We report two AOSD patients treated with TOC and review of the current data on the use of TOC in AOSD. TOC was applied to the first patient after failure of cloroquin, methotrexate, adalimumab and etanercept. The second patient received TOC because of inefficacious methotrexate treatment. TOC was well tolerated by both the patients, and no clinically significant side effects occurred. Including these two cases, a total of seven AOSD patients have been successfully treated with TOC so far. TOC may be a promising treatment option for AOSD patients refractory to conventional disease-modifying antirheumatic drugs anakinra and tumor necrosis factor-[Formula: see text].

show abstract

“…Pathologically it resembles systemic JIA and is considered an adult-onset type of systemic JIA. Several case and pilot studies have reported that tocilizumab treatment improved clinical symptoms and signs of AOSD patients who had been refractory to conventional treatments [Iwamoto et al, 2002;Nakahara et al, 2009;De Bandt and Saint-Marcoux, 2009;Matsumoto et al, 2009;Cunha et al, 2010;Sumida et al, 2010;Yoshimura et al, 2010;Perdan-Pirkmajer et al, 2010;Puechal et al, 2011;Rech et al, 2011]. The clinical efficacy of tocilizumab suggests that it may become a first-line biologic for the treatment of AOSD.…”

Section: Adult-onset Still's Diseasementioning

confidence: 99%

Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders

Tanaka

Hagihara

Shima

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

The cytokine interleukin (IL)‐6 has a wide range of biological activities. It contributes to host defense against pathogens by inducing immune responses, hematopoiesis, and acute‐phase reactions. However, dysregulation of IL‐6 production plays a significant pathological role in various autoimmune and chronic inflammatory disorders. Because IL‐6 blockade was anticipated to provide a novel strategy for the treatment of such diseases, tocilizumab, a humanized anti‐IL‐6 receptor antibody, was developed. Clinical trials have demonstrated the efficacy of tocilizumab for patients with moderate to severe rheumatoid arthritis, resulting in approval in more than 90 countries worldwide of this innovative biologic for the treatment of rheumatoid arthritis. Tocilizumab was also approved in Japan for the treatment of Castleman's disease and juvenile idiopathic arthritis. Results of recent pilot or case studies have indicated that tocilizumab may become a novel drug for various other autoimmune disorders, including systemic lupus erythematosus, systemic sclerosis, polymyositis, and vasculitis syndrome, as well as inflammatory disorders such as adult‐onset Still's disease, Crohn's disease, amyloid A amyloidosis, polymyalgia rheumatica, and spondylarthritides. It has been demonstrated that an imbalance of CD4‐positive T‐helper subsets [Th17 and/or Th1 >> regulatory T cells (Treg)] plays a major role in the development of several autoimmune disorders. In murine models of autoimmune disorders, the anti‐IL‐6 receptor antibody induced Treg and inhibited Th17 and/or Th1 differentiation, indicating that tocilizumab treatment may be able to repair this imbalance in human diseases as well. Drug Dev Res 72:717–732, 2011. © 2011 Wiley Periodicals, Inc.

show abstract

The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease

Cited by 18 publications

References 9 publications

Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature

Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders

Contact Info

Product

Resources

About